mRESVIA vaccin ARNm VRS ser pré 50 µg 1pce

7680699950010 Pharmacode 1137972 CH-69995 J07BX05 08.08.
mRESVIA vaccin ARNm VRS ser pré 50 µg 1pce
mRESVIA vaccin ARNm VRS ser pré 50 µg 1pce
mRESVIA vaccin ARNm VRS ser pré 50 µg 1pce
1 / 3
google

Details

GTIN
7680699950010
Pharmacode
1137972
Product number
6999501
CPT
-
Packaging group
1
Unit
Fertigspritze(n)
Composition
Suspension: mRNA-1345 0.10 mg/ml, heptadecan-9-ylis 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)-octanoas, cholesterolum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, 1,2-dimyristoyl-rac-glycero-3-polyethylenglycoli 2000 aether methylicus, trometamolum, trometamoli hydrochloridum, acidum aceticum glaciale, natrii acetas trihydricus, saccharum, aqua ad iniectabile, 1 ml corresp., natrium 0.017 mg pro dosi.

Articles (1)

mResvia 50µg/0.5ml, Injektionsdispersion
Injektionsdispersion
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
19/09/2026
Professional SmPC
Français
19/09/2026
Professional SmPC
Italien
19/09/2026
Patient information leaflet
Allemand
18/09/2026
Patient information leaflet
Français
18/09/2026
Patient information leaflet
Italien
18/09/2026

Detailed composition

Substance Quantity Type Category
mRNA-1345
0.1 MGML Substance Wirkstoff (Principe actif)
heptadecan-9-ylis 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)-octanoas
- Substance HNIDK
cholesterolum
- Substance HNIDK
1,2-distearoyl-sn-glycero-3-phosphocholinum
- Substance HNIDK
1,2-dimyristoyl-rac-glycero-3-polyethylenglycoli 2000 aether methylicus
- Substance HNIDK
trometamolum
- Substance HNIDK
trometamoli hydrochloridum
- Substance HNIDK
acidum aceticum glaciale
- Substance HNIDK
natrii acetas trihydricus
- Substance HNIDK
saccharum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
0.017 MG Substance HBESI

Authorization holder

Moderna Switzerland GmbH

4052 Basel

Authorization information

Swissmedic authorization number
69995
Drug name
mResvia, Injektionsdispersion
Galenic form
DISIJ
ATC Code
J07BX05
Authorization status
Z
Dispensation category
B
First authorization
17/04/2025
Authorization expiration date
16/04/2030
IT number
08.08.
Domain
Human medicine
Field of application
Aktive Immunisierung von Erwachsenen ab 18 Jahren zur Prävention von durch RSV verursachten Erkrankungen der unteren Atemwege

Packaging details

Description (FR)
mRESVIA vaccin ARNm VRS ser pré 50 µg 1pce
Description (DE)
mRESVIA RSV mRNA Impfstoff Fertspr 50 µg 1 Stk
Market launch
15/08/2025
Narcotic (BTM)
No

Application methods

IMU

Other packaging sizes

Buy us a coffee Explore the data